The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): Toxicity and efficacy in a nonselected group.
S. N. Banerjee
No relevant relationships to disclose
S. Mitchell
No relevant relationships to disclose
O. Al-Muderis
No relevant relationships to disclose
K. Pennert
No relevant relationships to disclose
A. Dunlop
No relevant relationships to disclose
C. Propert-Lewis
No relevant relationships to disclose
I. R. Judson
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; PharmaMar
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - ArQule; AstraZeneca; GlaxoSmithKline; Merck; Novartis; Pfizer; PharmaMar
M. R. Scurr
No relevant relationships to disclose